Survival difference in NSCLC and SCLC patients with diabetes mellitus according to the first-line therapy

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Nakazawa, Kensuke ^a   Kurishima, Koichi ^a   Tamura, Tomohiro ^a   Ishikawa, Hiroichi ^b   Satoh, Hiroaki ^a   Hizawa, Nobuyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Tsukuba Medical Center   (Japan)

Author keywords

Comorbid; Diabetes mellitus; Hemoglobin A1c; Prognostic factor, Lung cancer; Survival

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DIABETES MELLITUS; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; KAPLAN MEIER METHOD; LUNG TUMOR; MORTALITY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DIABETES MELLITUS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880631549     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0367-9     Document Type: Article

References (23)

1. Hanbali A, Al-Khasawneh K, Cole-Johnson C, Divine G, Ali H. Protective effect of diabetes against metastasis in patients with non-small cell lung cancer. Arch Intern Med. 2007;167(5):513.
2. Satoh H, Ishikawa H, Kurishima K, Ohtsuka M, Sekizawa K. Diabetes is not associated with longer survival in patients with lung cancer. Arch Intern Med. 2001;161(3):485.
3. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003;103(6):792-802.
4. Vasic L. Locally advanced non-small cell lung cancer - pretreatment prognostic factors: disease stage, tumor histopathological characteristics, the patient-related factors. Arch Oncol. 2007;15(1):19-23.
5. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-41.
6. De Giorgio R, Barbara G, Cecconi A, Corinaldesi R, Mancini AM. Diabetes is associated with longer survival rates in patients with malignant tumors. Arch Intern Med. 2000;160(14):2217.
7. Hatlen P, Grønberg BH, Langhammer A, Carlsen SM, Amundsen T. Prolonged survival in patients with lung cancer with diabetes mellitus. J Thorac Oncol. 2001;6(11):1810-7.
8. Luo J, Chen YJ, Chang LJ. Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2012;76(2):242-7.
9. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg. 1996;83(5):625-31.
10. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, et al. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. Cancer. 2001;91(5):957-63.
11. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285(7):885-92.
12. Lababede O, Meziane M, Rice T. Seventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagrams. Chest. 2011;139(1):183-9.
13. Cox DR. Regression models and life tables. J Roy Stat Soc B. 1972;34(1):187-220.
14. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer. 2007;120(9):1986-92.
15. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005;2(1):48-53.
16. Rosenzweig SA, Atreya HS. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol. 2010;80(8):1115-24.
17. Bähr C, Groner B. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors. 2005;23(1):1-14.
18. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46(13):2369-80.
19. Simon D, Balkau B. Diabetes mellitus, hyperglycaemia and cancer. Diabetes Metab. 2010;36(3):182-91.
20. Fidler MJ, Shersher DD, Borgia JA, Bonomi P. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol. 2012;4(2):51-60.
21. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159-69.
22. Yap TA, Olmos D, Molife LR, de Bono JS. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Expert Opin Investig Drugs. 2011;20(9):1293-304.
23. Ozkan EE. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol. 2011;344(1-2):1-24.